Figure S7. Effect of AZD9291 and AZ5104 in transgenic models of EGFR-TKI sensitizing (C/L858R and C/ex19del) and T790M resistant (C/L+T) lung cancer.

A, Preliminary study showing 5mg/kg/day of AZD9291 can induce significant tumor shrinkage in a lung tumor-bearing C/ex19del animal after one and two weeks of treatment as measured by MR imaging.

B, AZ5104 induces shrinkage in transgenic tumor models. Change in radiographic tumor volume from baseline by treatment for individual lung tumor-bearing C/L858R and C/L+T animals. Graphed is the percentage change in tumor volume, calculated for individual animals pretreatment and after treatment with vehicle, afatinib (7.5 mg/kg/d), or AZ5104 (5 mg/kg/d).

C, D, Representative MR images and H&E-stained sections (right panel; original magnification, ×40) of lungs from tumor-bearing C, C/L858R mice D, C/L+T mice pretreatment and after treatment with vehicle or AZ5104 for 1 week. H – heart; arrow denotes tumor.